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Abstract
OM-85 (Broncho-VaxomH, Broncho-MunalH, OmmunalH, PaxoralH, VaxoralH), a product made of the water soluble fractions
of 21 inactivated bacterial strain patterns responsible for respiratory tract infections, is used for the prevention of recurrent
upper respiratory tract infections and acute exacerbations in chronic obstructive pulmonary disease patients. OM-85 is able
to potentiate both innate and adaptive immune responses. However, the molecular mechanisms responsible for OM-85
activation are still largely unknown. Purpose of this study was to investigate the impact of OM-85 stimulation on human
dendritic cell functions. We show that OM-85 selectively induced NF-kB and MAPK activation in human DC with no
detectable action on the interferon regulatory factor (IRF) pathway. As a consequence, chemokines (i.e. CXCL8, CXCL6, CCL3,
CCL20, CCL22) and B-cell activating cytokines (i.e. IL-6, BAFF and IL-10) were strongly upregulated. OM-85 also synergized
with the action of classical pro-inflammatory stimuli used at suboptimal concentrations. Peripheral blood mononuclear cells
from patients with COPD, a pathological condition often associated with altered PRR expression pattern, fully retained the
capability to respond to OM-85. These results provide new insights on the molecular mechanisms of OM-85 activation of the
immune response and strengthen the rational for its use in clinical settings.
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Introduction
In the last ten years, it has become increasingly clear that
dendritic cell (DC) activation is one of the key steps leading to the
induction and polarization of the immune and inflammatory
response. The innate immune system sense microbes by multiple
classes of pattern recognition receptors (PRR), including Toll-like
receptors (TLR), NOD-like receptors (NLR), RIG-1-like receptors
(RLR) and C-type lectins. As sentinels of the immune system, DC
express a vast repertoire of PRR [1–3]. Pathogen recognition by
PRR activates a transcriptional program leading to the synthesis of
molecules required for a rapid, efficient and pathogen-tailored
immune-response. For example, PRR sensing extracellular
microbes (such as TLR2, TLR5 and some C-type lectins) activate
a NF-kB- and MAPK-dependent production of pro-inflammatory
cytokines, while PRR recognizing intracellular pathogen-associat-
ed molecular patterns (PAMP) (e.g. TLR7-9 and RIG-1) lead to
the activation of the interferon regulatory factor (IRF) family of
transcription factors and to the production of type I Interferons.
Notably TLR4, which senses lipolysaccharide (LPS) as well as
other microbial and endogenous danger signals, is known to
activate both pathways. Pathogen recognition also induces DC
maturation to professional antigen presenting cells, characterized
by the expression of co-stimulatory molecules and by a ‘‘switch’’ in
the expression of chemotactic receptors that enables them to travel
to secondary lymphoid organs, where they meet naı¨ve T cells [4].
OM-85 (Broncho-VaxomH, Broncho-MunalH, OmmunalH,
PaxoralH, VaxoralH) is the lyophilisate of the water soluble
fractions of 21 strain lysates from the following species, which are
commonly found in respiratory tract infections: Haemophilus
influenzae, Streptococcus (Diplococcus) pneumoniae, Klebsiella pneumoniae
ssp. pneumoniae et ssp. ozaenae, Staphylococcus aureus, Streptococcus pyogenes
et sanguinis (viridans), Moraxella (Branhamella/Neisseria) catarrhalis.
Despite OM-85 is used in the prevention of recurrent infections
of the airways and acute exacerbations in chronic obstructive
pulmonary disease (COPD) [5,6], little is known about the
molecular mechanisms underlying these effects. Bacterial lysates
have been empirically, yet extensively, used in the prophylaxis of
infections since the beginning of the XX century. The rational for
this approach was to stimulate an antibody response against
pathogens that may protect mucosal surfaces. According to the
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current view of DC biology, orally administered bacterial antigen-
based drugs may activate mucosal DC by acting as PRR ligands.
In turn, DC would induce antigen-specific T lymphocytes
contributing to the isotype switch towards IgA via the secretion
of cytokines such as transforming growth factor- b (TGF-b) or
members of the tumor necrosis factor (TNF) family such as B-cell
activating factor (BAFF) and a proliferation-inducing ligand
(APRIL) [7]. After maturation, IgA-producing plasmablasts get
into the blood stream and preferentially home to mucosal-
associated lymphoid tissues of different organs including the
airways [7]. Consistent with this view, the protective effect of OM-
85 in a model of type I diabetes was found to depend on the
presence of TGF-b [8], while human studies indicated that OM-
85 increased the content of secretory IgA in bronchoalveolar
lavage fluid [9]. In addition, several works indicated that OM-85
may act on DC [8,10,11], but the mechanisms underlying this
interaction and its biological outcomes have never been investi-
gated thoroughly.
Aim of the present research was to systematically investigate the
activation properties of OM-85 on human DC subsets. Here, we
report that OM-85 activates human DC via the NF-kB and
MAPK pathways. This results in a mild pro-inflammatory
activation of DC that release selected cytokines and chemokines,
which in turn may favor the recruitment of innate effector cells to
epithelial surfaces and promote lymphocyte function. This effect is
increased by the presence of suboptimal concentrations of pro-
inflammatory stimuli mimicking a pre-existing, subclinical bacte-
rial colonization.
Materials and Methods
Ethics statement
The study was approved by the Ethical Committee Intercom-
pany A.O.U San Giovanni Battista and A.O.C.T.O Maria
Adelaide (Turin, Italy) and conformed to the principles of the
declaration of Helsinki. Blood was taken for routine diagnostic
tests and patients provided their written informed consent.
Cell preparation and culture
Peripheral blood mononuclear cells (PBMC) were isolated from
buffy coats of healthy blood donors (through the courtesy of the
Centro Trasfusionale, Spedali Civili di Brescia, Brescia, Italy) by
Ficoll gradient (Ficoll-PaqueTM Plus, GE Healthcare, Israel).
Highly enriched blood monocytes were obtained from PBMCs by
immunomagnetic separation using anti-CD14-conjugated mag-
netic microbeads (Miltenyi Biotech, Germany). DC were differ-
entiated from monocytes cultured for 6 days at 86105/ml in tissue
culture plates in RPMI 1640 complemented with 10% FCS,
50 ng/ml GM-CSF (ProSpec Technogene, Israel) and 20 ng/ml
IL-4 (ProSpec Technogene). Myeloid (MDC) and plasmacytoid
dendritic cells (PDC) were immunomagnetically sorted with anti-
blood antigens BDCA-1 and BDCA-4 cell isolation kits respec-
tively (Miltenyi Biotech) [12,13]. DC maturation was induced by
incubation with the indicated concentrations of LPS (Escherichia coli
055:B5, Sigma-Aldrich, USA) or OM-85 (OM PHARMA,
Switzerland) for 24 hours (16106 DC/ml). The bacterial endo-
toxin content of OM-85 was 0.300 EU/ml (0.03 ng/ml) as
determined by the producer using the EndosafeH-PTSTM, a
handheld spectrophotometer that utilizes FDA-licensed disposable
cartridges based on the LAL (Limulus Amoebocyte Lysate)
method (USP,85.Bacterial Endotoxins Test, chromogenic
technique; Eur. Ph. 2.6.14. Bacterial Endotoxins, Method D.
Chromogenic kinetic method). Where indicated, cells were
stimulated with 1 ng/ml or 10 ng/ml TNF-a and 500 U/ml
IFNc (ProSpec Technogene), PDC were stimulated with 2 mg/ml
CpG 2116 (Invivogen, Ca, USA) or OM-85 in the presence of
20 ng/ml IL-3 (ProSpec Technogene).
Polymorphonuclear Neutrophils (PMN) were isolated after
Ficoll and 4% Dextran (Sigma Aldrich) gradient separation. To
lyse red blood cells, collected neutrophils were treated with 0.2%
NaCl (500) and 1.2% NaCl (Sigma Aldrich). Highly purified blood
PMN were obtained by using ‘‘Human Neutrophil Enrichment
Kit’’ and ‘‘Purple EasySep Magnet’’ (StemCell Technologies,
USA) according to the manufacturer’s instructions.
THP-1 (human acute monocytic leukaemia cell line) were
purchased from American Type Culture Collection (ATCC,
Manassas, VA, USA) and were cultured in RPMI 1640
complemented with 10% FCS.
Cytoplasmic and nuclear extracts preparation
Cytoplasmic proteins were separated in L1 buffer (50 mM Tris-
HCl, pH 8.0; 2 mM EDTA; 0.1% NP-40 and 10%glycerol) with
inhibitors (1 mM Na3VO4, 2 mM DTT, 1 mM NaF, 1 mM
PMSF and Protease Inhibitors Cocktail, all reagents were
purchased from Sigma-Aldrich). Nuclear pellets were washed
twice with L1 buffer with inhibitors and then lysed in NP-40 Lysis
buffer (50 mM Tris-HCl, pH 8.0; 250 mM NaCl; 1 mM EDTA;
0.1% NP-40 and 10% glycerol) with inhibitors. Quantification of
protein content was performed by Bradford method according to
standard protocols.
Western Blot
Equal amounts of cytoplasmatic or nuclear extracts were boiled
for 5 minutes in a loading buffer containing 5% glycerol, 0.001%
bromophenol blue, 4.5% SDS and 10% 2-mercaptoethanol.
Samples were run through 6–12% polyacrylamide gel and
electrophoretically transferred to PDVF membrane (Immobi-
lionTM, Millipore, Bedford, MA). After blocking of aspecific
binding (1% BSA, Sigma-Aldrich), membranes were incubated
with the indicated primary antibodies (NF-kB p65, IkBa, ATF2
and c-Jun and b-actin from Santa Cruz Biotechnology, Ca;
pERK1/2 from Cell Signalling Technologies, Massachusetts,
USA; Lamin A/C from Serotec, UK) for 1 hour at room
temperature and then incubated with peroxidase-conjugated
secondary antibody (1:5000; anti-rabbit-HRP; Santa Cruz Bio-
technology) for 45 minutes at room temperature. Super SignalH
West Pico Chemiluminescent Substrate (Pierce, Rockford, USA)
was used to visualize protein bands.
Electro Mobility Shift Assay (EMSA)
NF-kB DNA binding activity was assessed by EMSA by using
the IgG-kB probe (FAM Biotech srl, Brescia, Italy) [14]:
GTACGGAGTATCCAGTTGAGGGGACTTTCCCAGGC.
Non-radioactive EMSA was performed using DIG Gel Shift
Kit, 2nd Generation (Roche, Mannheim, Germany), according to
the manufacturer’s instructions. Briefly: single stranded oligonu-
cleotides were annealed and 39end-labeled with digoxigenin-11-
ddUTP through Terminal Transferase. Labeled DNA fragments
containing the sequence of interest were incubated with nuclear
cell extracts (see above), binding buffer, poly [d(I-C)], poly L-
lysine, and/or unlabeled oligonucleotide (125-fold excess) for
EMSA competition, and/or specific antibody (1 mg/sample) for
supershift assays. Following a 15 minute-incubation at room
temperature, the reactions were transferred into a pre-runned
6% native polyacrylamide mini-gel (0.75 mm thick) and submitted
to gel electrophoresis (120 V, 1 hour). Following electrophoretic
separation, oligonucleotide-protein complexes were transferred by
electro-blotting (400 mA, 30 minutes) onto specific positively
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charged nylon membranes (Roche) and detected using an anti-
digoxigenin antibody conjugated with alkaline phosphatase,
revealed by autoradiography upon application of a specific
luminescent substrate (CSPD, Roche). The generated chemilumi-
nescent signals were recorded on X-ray films.
Reporter plasmid preparation and luciferase assay
A NF-kB reporter plasmid was prepared for stable transfection.
The pGL4.27 [luc2P/minP/Hygro] vector (Promega, USA), was
selected as the backbone. A tandem of three NF-kB responsive
elements [14] were cloned into the pGL4 vector using the NheI
and BglII sites of the multiple cloning region to generate the
pGL4-kB reporter plasmid. THP1 transfection was performed
using AmaxaH Cell Line NucleofectorH Kit V (Lonza Cologne
AG, Germany), according to the manufacturer’s instructions.
48 hours later, cells were put into selection with 200 mg/ml of
Hygromycin B (Calbiochem, Merck Chemicals Ltd., UK) as
assessed by previously performed viability experiments. Luciferase
assay was performed using ONE-GloTM Luciferase Assay System
(Promega), according to the manufacturer’s instructions. Quanti-
LumH Recombinant Luciferase (Promega) was used for preparing
the luciferase standard curve according to the manufacturer’s
instructions.
Chemotaxis
PMNs migration was evaluated using a chemotaxis micro-
chamber technique (NeuroProbe, Pleasanton, CA) using a PVP-
free polycarbonate filter (5 mm pore size; NeuroProbe). The
chamber was incubated at 37uC for 60 minutes. At the end of the
incubation, filters were removed and stained with Diff-Quik
(Baxter, Rome, Italy), and 5 high-power oil-immersion fields
(magnification 10006) were counted. All experimetal points were
performed in triplicate. DC supernatants were diluted in RPMI to
obtain a chemotaxis medium at 1% FCS concentration. For
inhibition experiments, 10 mM purified recombinant M3 (a gift
from A. Alcami, Centro de Biologia Molecular Severo Ochoa,
Madrid, Spain), a broad specificity chemokine-binding protein,
was added to the RPMI used to diluted the supernatants,
immediately prior of the chemotactic assay. To block G protein-
coupled receptors (GCPR) cells were incubated 90 minutes at
37uC with 750 ng/ml of Bordetella Pertussis Toxin (Calbiochem, San
Diego, CA) and then washed and resuspended in fresh medium
before the assay.
Real-time PCR
RNA was extracted using TRIzolH reagent, according to the
manufacturer’s instructions. After RNA purification, sample were
treated with DnaseI to remove contaminating genomic DNA.
Reverse transcription was performed using random hexamers and
M-MLV RT. All reagents were purchased from Invitrogen. Gene-
specific primers were purchased from FAM Biotech. Sequences
are the following: hHPRT forward, 59-CCAGTCAACAGGG-
GACATAAA-39, and hHPRT reverse, 59-CACAATCAAGA-
CATTCTTTCCAGT-39; hIL-6 forward, 59-CACACAGA-
CAGCCACTCACCTC-39, and hIL-6 reverse, 59-
TCTGCCAGTGCCTCTTTGCTGC-39; hCXCL8 forward, 59-
AGACAGCAGAGCACACAAGC-39, and hCXCL8 reverse, 59-
ATGGTTCCTTCCGGTGGT-39; hIkBa forward, 59-
GTCAAGGAGCTGCAGGAGAT-39, and hIkBa reverse, 59-
ATGGCCAAGTGCAGGAAC-39; hTNF-a forward, 59-
CAAGCCTGTAGCCCATGTTGTAG-39, and hTNF-a reverse,
59-CCTGGGAGTAGATGAGGTACAGG39; hCOX-2 forward,
59-gctttatgctgaagccctatga-39, and hCOX-2 reverse, 59-tccaactctg-
cagacatttcc-39;’. The iQTM Sybr Green Supermix (Bio-Rad
Laboratories Inc., Hercules, CA, USA) was used to run relative
quantitative real-time PCR of the samples according to the
manufacturer’s instructions. Reactions were run in triplicate on an
iCyclerTM (Bio-Rad Laboratories Inc.) and generated products
analysed with the iCyclerTM iQ Optical System Software (Version
3.0a, Bio-Rad Laboratories Inc.). Gene expression was normalized
based on HPRT mRNA content. Data are displayed as 22DDCt
values.
ELISA
Human IL-6, IL-10, IL-12p70, CCL3, CCL20, CCL22,
CXCL1, CXCL6, CXCL8 and APRIL protein levels in superna-
tants were measured by DuoSetH sandwich ELISA according to
the manufacturer’s instructions (DuoSetH ELISA Development
System, R&D System, Minneapolis, USA). Human IFNa and
BAFF protein levels were measured by sandwich ELISA from
Bender (Austria) and Adipogen (CH) according to the manufac-
turers’ instructions.
PBMC and MoDC preparation from healthy and COPD
patients
A total of seven COPD patients were enrolled while the control
group consisted of seven healthy volunteers. Clinical information
of patients are listed in Table 1. Peripheral blood mononuclear
cells were isolated from whole blood samples of patients and
healthy donors by Ficoll gradient. Monocytes and MoDC were
prepared as described for buffy coats. 16106 PBMC or MoDC/ml
were stimulated with the indicated concentrations of OM-85 (OM
PHARMA) for 24 hours. Where indicated, cells were stimulated
with 100 ng/ml TNF-a and 500 U/ml IFNc. Supernatants were
collected and tested by ELISA.
Statistical analysis
Comparisons among treatments were performed by Student’s t-
test, by Dunnett’s Multiple Comparison Test or by analysis of
variance, as appropriate and as indicated in figure legends.
Results
Activation of the NF-kB and MAPK pathways by OM-85 in
human monocyte derived DC (MoDC)
Triggering of most of the known PRR activates the cascade
leading to NF-kB nuclear translocation and transactivating
activity. In order to test the capability of OM-85 to induce NF-
kB nuclear translocation in human MoDC, we performed cell
fractionation and western blot analysis (Figure 1). As expected,
LPS induced IkBa degradation (Figure 1A, center panel) and p65
nuclear translocation at 60 minutes (upper panel). Interestingly,
IkBa degradation and p65 nuclear translocation could also be
observed when cells were stimulated with OM-85 although with a
slower kinetic and in a weaker manner. OM-85 also induced NF-
kB DNA-binding activity with a kinetic similar to that observed in
western blot experiments (Figure 1B, upper panel). Supershift
experiments (Figure 1B, lower panel) demonstrated that p65 is the
NF-kB family member mostly involved in MoDC activation by
OM-85. These findings are further supported by the evidence that
OM-85 induced significant luciferase expression by a reporter NF-
kB plasmid stably transfected in THP1 cells, although being less
potent than LPS (Figure 1C). Since the signaling pathways that
activate NF-kB also activate MAPK, the effects of OM-85 was also
investigated on key events of the MAPK cascade. Figure 1D shows
that OM-85 induced both ERK1/2 phosphorylation and nuclear
translocation of activating transcription factor-2 (ATF2) and c-Jun,
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two members of the activating protein-1 (AP-1) family of
transcription factors. On the contrary, no p38 phosphorylation
could be detected in these experimental conditions (not shown).
The activation of these two pathways was also investigated by
real time PCR. Figure 1E shows that OM-85 induced the
accumulation of MAPK and/or NF-kB target gene mRNA. In
some cases, such as for IkBa, CXCL8, caspase 1 and JUNB (upper
row), the induction was similar to that observed with LPS, while
other genes (such as TNF-a, IL1b, IL-6 and Cyclooxygenase-2,
lower row) were induced in a weaker manner.
Of interest, we found that OM-85 did not activate the IRF
pathway since no nuclear translocation of IRF3 and IRF7 could
be detected by western blot, nor DNA-binding activity by EMSA
(Figure S1A and B). These negative results were reinforced by no
induction of known IRF target genes, such as IRF1, IRF3, IRF5,
IRF7, CXCL9, CXCL10 and IFNb1 (Figure S1C and not shown).
Also, no secretion of the IFNb1 protein could be detected by
ELISA (Figure S1D).
OM-85 induces B cell activating cytokines and promotes
PMN recruitment
Activated DC shape the immune response through the secretion
of pro- and anti-inflammatory cytokines. Thus, the ability of OM-
85 to regulate cytokine and chemokine production was investi-
gated in MoDC (Figure 2). Among the cytokines investigated,
OM-85 induced the secretion of IL-6 and BAFF. In addition,
OM-85 induced the release of the chemokines CCL2, CCL3,
CCL20 and CCL22 in a dose-dependent manner and with a
strength comparable to LPS (Figure 2A). Interestingly, OM-85
potently stimulated the production of the PMN-attracting
chemokines CXCL8 , CXCL6 and CXCL1 (Figure 2A and not
shown). Boyden chamber experiments showed that supernatants of
OM-85-stimulated MoDC were active in inducing the migration
of freshly purified blood PMN and that this activity was inhibited
by cell pretreatment with Bordetella pertussis toxin, an inhibitor of
GaI protein, and M3, a viral chemokine binding protein [15]
(Figure 2B); OM-85 per se was not chemotactic for PMN (not
shown). In our experimental conditions, OM-85 did not signifi-
cantly enhance the secretion of other pro-inflammatory, antiviral
and chemotactic mediators, such as TNF-a, IL-1b, IFNb1, IL-12,
IL-23, APRIL, CCL4, CCL19 and CXCL10 (Figure S1D and not
shown).
Synergistic interaction of OM-85 and pro-inflammatory
agonists for cytokine production
The ability of OM-85 to induce cytokine production in the
presence of pro-inflammatory or immuno-activating stimuli was
then investigated. Figure 3A shows that the induction of IL-6 is
potently enhanced (3 to 4-fold) in the presence of inactive IFNc
concentrations. Similarly, OM-85 induced a three-fold increase in
the IFNc/LPS-induced release of IL-10, an anti-inflammatory, B
cell activating cytokine (Figure 3B).
In a second set of experiments the action of OM-85 was
investigated in the presence of bacterial (LPS) or pro-inflammatory
(TNF-a) agonists. First, we focused on the effect of suboptimal
concentrations of LPS (0.01 ng/ml) and OM-85 (10 mg/ml). As
shown in Figure 3C, this combination strongly upregulated the
release of CXCL8, CXCL1 and CXCL6 (not shown), at levels
similar to those obtained with singular optimal concentrations of
the two agonists (see Figure 2). Furthermore, the effect of an
optimal OM-85 concentration (1 mg/ml) on CXCL8 production
was also strongly increased by optimal (10 ng/ml) and suboptimal
(1 ng/ml) TNF-a concentrations (Figure 3D).
Activation of blood purified DC subsets by OM-85
MDC and PDC were isolated from the blood of three
independent donors and stimulated with 100 mg/ml or 1000 mg/
ml OM-85 for 24 hours. LPS+IFNc and CpG were respectively
used as MDC and PDC prototypic activators. In agreement with
the results obtained with MoDC, OM-85 induced the secretion of
CXCL8 by MDC (Figure 4A) and IFNa by PDC (Figure 4B).
Consistently with the results obtained with MoDC, OM-85 did not
stimulate MDC to produce IL-12, IL-23 and CXCL10 (not
shown).
OM-85 activates cytokine production by immune cells
from COPD patients
OM-85 treatment is currently recommended in the prevention
of acute exacerbations in COPD [5–6], a pathological condition
often associated with alterations of the expression profile of PRR
Table 1. Characteristic of COPD patients enrolled in the study.
Name Age Sex Age diagnosed COPD Disease stadium Therapy Notes
P1 84 M 64 Severe Inhaled b2 agonist bronchodilatator,
inhaled anticholinergics
Chronic respiratory failure
(O2 therapy)
P2 73 F 57 Moderate/severe Inhaled b2 agonist bronchodilatator,
inhaled anticholinergics
None
P3 68 F 55 Severe Inhaled b2 agonist bronchodilatator,
inhaled steroid, inhaled anticholinergics
Chronic respiratory failure
(O2 therapy)
P4 74 F 60 Very severe Inhaled b2 agonist bronchodilatator,
inhaled steroid, inhaled anticholinergics,
frequent administration of courses of
antibiotics for chronic bronchial infection
Chronic respiratory failure
(O2 therapy)
P5 66 M 56 Severe Inhaled b2 agonist bronchodilatator,
inhaled steroid
Smoker
P6 56 M 55 Faint Inhaled anticholinergics Smoker
P7 65 M 64 Very severe Inhaled b2 agonist bronchodilatator,
inhaled steroid, inhaled anticholinergics
None
Table reports the main features (age, sex, age at diagnosis of COPD, disease stadium, therapy and notes) of selected patients (P).
doi:10.1371/journal.pone.0082867.t001
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Figure 1. Activation of the NF-kB and MAPK pathways by OM-85 in MoDC. A) Immature human MoDC were stimulated with 100 mg/ml
OM-85 for 30, 60, 90 and 120 minutes. 100 ng/ml LPS was used as a positive control. After cell lysis and protein fractionation, cytoplasmic (Cyto) and
nuclear (Nuclei) extracts were blotted against NF-kB p65 and IkBa. b-actin and Lamin A/C represent loading controls for cytoplasmic and nuclear
proteins respectively. The image depicts results obtained in one representative donor out of eight. B) EMSA (upper panel) and supershift (lower
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[16]. Thus, we set out to confirm previous results on cells from
COPD patients. Given that we usually receive few ml of patients’
blood which do not allow the purification of MDC, we choose to
work with PBMC, which can be obtained in reasonable numbers
panel) showing the induction of NFkBp65-DNA binding activity by OM-85 in human moDC stimulated as in A). Signal specificity was assessed by
competing each sample with a 125-fold excess unlabeled probe (lanes 2,4,6,8,10 upper panel). The image depicts results obtained in one
representative donor out of four. C) OM-85 induces the production of luciferase in THP1 cells bearing a NF-kB-reporter plasmid (NF-kB pGL4, striped
histograms). THP1 cells were stimulated with 1 mg/ml LPS and 1000 mg/ml OM-85. As expected, THP1 untransfected cells (untransfected, empty
histograms) did not produce luciferase in response to stimulation. Similar results were obtained when cells were transfected with the pGL4 empty
backbone (pGL4, black histograms). Results are expressed as mean+/2SD of three independent experiments. *P value,0.01 by Dunnett’s Multiple
Comparison Test. D) OM-85 activates the MAPK pathway. Cell extracts prepared as in A) were blotted with antibodies specific for phophorilated
ERK1/2 (Cyto, upper panel) and total ATF2 and c-Jun (Nuclei, lower panel). b-actin and Lamin A/C represent loading controls for cytoplasmic and
nuclear proteins respectively. The image depicts results obtained in one representative donor out of three. E) OM-85 induces NF-kB- and MAPK-
dependent gene transcription. Immature MoDC were stimulated with 100 mg/ml OM-85 (open circles) and 100 ng/ml LPS (black circles) for 2, 4, 8 and
24 hours. After RNA extraction, reverse transcription and DNAse I digestion, samples were amplified by Q-PCR using gene-specific primers. Results
represent means+/2SE of three independent donors and are expressed as fold induction (FI) over unstimulated samples (0).
doi:10.1371/journal.pone.0082867.g001
Figure 2. Induction of selected cytokines and chemokines by OM-85 in MoDC. A) MoDC (106/ml) were stimulated with OM-85 as indicated
and with 100 ng/ml LPS (IL-6, BAFF, CCL2, CXCL8 and CXCL6) or 10 ng/ml LPS (CCL3, CCL20 and CCL22) as a positive control. After 24 hours,
supernatants were collected and analyzed by ELISA. Ut = untreated. *P,0.05 and **P,0.01 by Dunnett’s Multiple Comparison Test. B) Supernatants
of MoDC stimulated with OM-85 induce a G-protein-dependent migration of PMN. As a comparison, migration of PMN was elicited with unstimulated
supernatants+CXCL8 and PMA. As expected, migration to CXCL8 was inhibited by both 10 nM M3 and 750 ng/ml, Pertussis toxin (P.Tox) while
migration to PMA was not. Results are expressed as chemotactic index over migration to supernatants of unstimulated MoDC and represent means+/
2SD of three independent Boyden chamber experiments. *P value,0.05 and ** P value,0.01 by Dunnett’s Multiple Comparison Test.
doi:10.1371/journal.pone.0082867.g002
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from small amounts of blood and well represent the myeloid
compartment of circulating cells. PBMC from COPD patients and
healthy controls were stimulated with OM-85 and/or 500 U/ml
IFNc or 100 ng/ml TNF-a. As expected based on previous results,
in response to OM-85 PBMC produced IL-6, IL-10, CXCL8,
CXCL1, CCL20 and CCL22 (Figure 5A). In these experimental
conditions, PBMC also produced low concentration of CXCL6
(0.3260.09 ng/ml for 100 mg/ml OM-85; 0.360.11 ng/ml for
1000 mg/ml OM-85; n = 7, not shown).On the other hand,
IL12p70, CXCL10 and BAFF release was below the assay
detection limits.
In order to confirm at least part of these results on DC, that are
the real focus of this work, we differentiated MoDC from blood of
patients and healthy controls. Given the low number of MoDC
recovered at the end of the differentiation process, we decided to
concentrate our analysis on IL-6, IL-10 and CXCL8, for which a
statistically higher production was detected in patients’ PBMC.
Figure 5B shows the results for IL-6 and CXCL8, while IL-10 was
undetectable in these experimental conditions.
These experiments demonstrate that immune cells from COPD
patients fully retain the capability to respond to OM-85. In
addition, they show that COPD patients display a tendency to
release higher levels of cytokines when stimulated with OM-85
alone or in combination with IFNc or TNF-a, although this
difference is statistically significant only in the case of IL-10 and
CXCL8 for PBMC and IL-6 for MoDC (Figure 5).
Discussion
Previous work reported that OM-85 has immunomodulating
properties and may act on human DC by promoting DC
maturation and T cell activation [11]. However, in order to elicit
a full, pathogen-tailored immune response, DC must also secrete
proper soluble mediators [17]. Here, we report that OM-85
induces the secretion of a defined set of cytokines by human DC
through the NF-kB and MAPK pathways, which are activated
downstream of the vast majority of PRR. By contrast, OM-85 did
not activate the IRF pathway in these cells and experimental
conditions, thus suggesting that TLR4, endosomal TLR and RLR
may not be involved in OM-85 recognition and signaling. This
conclusion contrasts with published data showing that activation of
murine splenocytes by OM-85 was dramatically reduced in both
TLR22/2 and TLR42/2 mice [8]. Nevertheless, species-
specific differences may well explain such apparent discrepancy
in TLR usage. The identification of the receptor/s triggered by
OM-85 in human DC would be of great importance. We reasoned
Figure 3. Synergism between OM-85 and pro-inflammatory agonists in MoDC.MoDC (106/ml) were stimulated as indicated. After 24 hours,
supernatants were collected and analyzed by ELISA. *P,0.05 and **P,0.005 by paired Student’s t test.
doi:10.1371/journal.pone.0082867.g003
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that, since OM-85 is a complex mixture of water soluble fractions
from several bacterial strains, it is conceivable that cell activation
does not rely on a single PRR, but depends instead on a number of
PRR of different classes. Thus, we have started to investigate the
activation of HEK293 cells transfected with single receptors.
Preliminary data show that OM-85 triggers the production of
CXCL8 in cells transfected with NOD1 and NOD2. In a different
set of experiments, HEK293 cells were transfected with different
TLR or NOD2 together with a reporter plasmid. Here, we
detected some reporter activity in cells expressing TLR2 and
NOD2. No signal could instead be activated by endosomal TLR,
thus apparently supporting our conclusion based on missing IRF
activation. However, these results are far from being conclusive
because transfectants for a number of PRR are still missing. For
example, since OM-85 contains peptidoglycans it is mandatory to
investigate the role of C-type lectins and scavenger receptors. In
addition, this strategy based on single transfectants may convey
insufficient information because many PRR do work in hetero-
dimers or even more intricate complexes, such as in the case of
CD36, a coreceptor for TLR2/6 when sensing well defined
PAMP. Thus, in order to depict the exact PRR pattern triggered
by OM-85 in human DC, we aim at targeting in this cell type the
most promising candidates identified by our screening experi-
ments.
The activation of the NF-kB and MAPK pathways is known to
lead to DC maturation and cytokine production. However, the
cytokine panel induced by OM-85 is consistently different with
respect to that induced by a prototypic, TLR4-dependent, DC
activating stimulus, such as LPS. First, OM-85 was a very poor
inducer of pro-inflammatory cytokines, exception made for the
secretion of moderate levels of IL-6. In addition, OM-85, alone or
in combination with IFNc did not induce IL-12p70 and IL-23,
two key TH1/TH17-polarizing cytokines. These results are in
agreement with the lack of IL-12 production previously reported
in a study performed using human lung fibroblasts stimulated with
phytohaemagglutinin, but conflicts with a study performed with
murine cells [8], strengthening the possibility that species-specific
differences should be considered when analyzing the action of
OM-85. In addition, OM-85 led to the production of BAFF and,
in the presence of IFNc+LPS, of IL-10. This panel of cytokine
secretion proposes a role for OM-85 in the activation of the
humoral arm, rather than the pro-inflammatory cellular arm, of
the immune response. Indeed, both IL-6 and IL-10 are key
mediators for B cell activation and survival [18–20] and BAFF is a
key cytokine for the T cell-independent production of IgA by B
cells [21]. This activation profile is conceivable with the induction
of IgG and IgA production observed following in vivo adminis-
tration of OM-85 in preclinical experimental models and in
patients [22–23].
Given that OM-85 is recommended in the treatment of COPD,
it is interesting to note that a similar cytokine profile was also
observed using cells obtained from COPD patients, suggesting that
the expression of the PRR involved in OM-85 recognition is not
altered in this reactive pathological condition. The fact that cells
from COPD patients tended to secrete more cytokines in response
to stimulation was not unexpected since it is well known that
inflammation is a central feature of COPD, which is characterized
by increased transcription of pro-inflammatory proteins such as
cytokines, chemokines, growth factors and enzymes [24]. In this
context, the observed increase of IL-10 secretion by COPD cells
might have a role in the control of excessive production of pro-
inflammatory mediators and tissue damage and may represent a
rationale for the usage of OM-85 in the prevention of acute
exacerbations in COPD patients [5–6].
A second mechanism of action emerging from this study is the
role of OM-85 in promoting the recruitment of immune effector
cells through the release of chemokines. Indeed, DC exposed to
OM-85 released increased levels of CCL2 and CCL3, two
chemokines active on monocytes and NK cells, and CCL20 and
CCL22, two chemotactic factors active at the epithelial surfaces
[25–27]. Of particular interest is the ability of OM-85 to induce a
PMN-skewed activation program through the production of
CXCL1, CXCL6 and CXCL8, three chemokines that binds
CXCR1 and CXCR2 on PMN. In agreement with these results,
supernatants of OM-85-stimulated DC were active in inducing
PMN migration in vitro. This finding supports a potential role of
OM-85 in the activation of the first line of innate defense against
bacterial infections. Of note, in the presence of sub-optimal
concentrations of LPS (as low as 0.01 ng/ml) even uneffective
concentrations of OM-85 became active in inducing the release of
granulocyte-attracting chemokines and a similar action was
observed in the presence of TNF-a, a master pro-inflammatory
cytokine. Thus, at least for selected targets, OM-85 may be
effective at lower concentrations when administered in the
presence of a pre-existing pro-inflammatory background.
Figure 4. Activation of primary DC subsets by OM-85. A) MDC
and B) PDC were isolated from buffy coats of three independent
healthy donors and stimulated as indicated (106/ml). After 24 hours,
supernatants were collected and analyzed by ELISA. *P,0.05 by
Dunnett’s Multiple Comparison Test.
doi:10.1371/journal.pone.0082867.g004
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Finally, we report that OM-85 induced PDC to release low
concentrations of IFNa, which represents the most important
cytokine for the defense against viral infections. Thus, OM-85 may
help to set up a basal antiviral state. This finding, while contrasting
with the lack of IFN-I induction in MoDC, stresses the cell-specific
mechanism of action and the importance to carefully evaluate the
individual pathways of activation elicited by OM-85 in different
target cells.
In conclusions, OM-85 induces a mild and well shaped human
DC activation that may contribute to the generation of a ‘‘pre-
alert state’’ resulting in an early protection towards incoming
infections. This study provides the first description of the
molecular basis for the activation of the immune system by OM-
85. The evidence that DC exposed in vitro to OM-85 activate
three distinct biological pathways to promote immune responses
support the therapeutic effects observed in vivo and stresses the
importance of a more detailed characterization of its mechanism
of action in clinical settings.
Supporting Information
Figure S1 Lack of IRF pathway activation by OM-85 in
MoDC. A) Immature human MoDC were stimulated with
100 mg/ml OM-85 for 30, 60, 90 and 120 minutes. 100 ng/ml
LPS was used as the positive control for IRF3 translocation, but it
does not represent a positive control for IRF7 translocation. After
cell lysis and protein fractionation, cytoplasmic (Cyto) and nuclear
(Nuclei) extracts were blotted against IRF3 and IRF7. b-actin and
Lamin A/C represent loading controls for cytoplasmic and
nuclear proteins respectively. The image depicts results obtained
in one representative donor out of eight. B) EMSA experiment
showing lack of IRF-DNA binding activity by OM-85 in human
moDC stimulated as in A). Signal specificity was assessed by
competing each sample with a 125-fold excess unlabeled probe
(lanes 2,4,6,8,10). The image depicts results obtained in one
representative donor out of four. C) OM-85 induces no IRF-
dependent gene transcription. Immature MoDC were stimulated
with 100 mg/ml OM-85 (open circles) and 100 ng/ml LPS (black
circles) for 2, 4, 8 and 24 hours. After RNA extraction, reverse
transcription and DNAse I digestion, samples were amplified by
Q-PCR using gene-specific primers. Results represent means+/
2SE of three independent donors and are expressed as fold
induction (FI) over unstimulated samples (0). D) OM-85 does not
induce IFNb1 secretion by MoDC. MoDC (106/ml) were
stimulated for 24 hours with LPS 100 ng/ml or OM-85
1000 mg/ml and supernatants analyzed by ELISA. *P,0.05 by
paired Student’s t test.
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